Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Bakasis AD, Mavragani CP, Voulgari PV, Gerolymatou N, Argyropoulou OD, Vlachoyiannopoulos PG, Skopouli FN, Tzioufas AG, Moutsopoulos HM. Bakasis AD, et al. Among authors: gerolymatou n. J Autoimmun. 2022 Jul;131:102846. doi: 10.1016/j.jaut.2022.102846. Epub 2022 Jun 9. J Autoimmun. 2022. PMID: 35717727 Free PMC article.
Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases.
Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E, Zampeli E, Gerolymatou N, Kataxaki E, Melissaropoulos K, Panopoulos S, Fragiadaki K, Evangelatos G, Bournia VK, Arida A, Karamanakos A, Pappa M, Panagiotopoulos A, Koutsianas C, Mparouta G, Dimitroulas T, Liossis SN, Tektonidou MG, Kravvariti E, Kougkas N, Georgiou P, Voulgari P, Elezoglou A, Bogdanos DP, Vassilopoulos D, Sfikakis PP. Papagoras C, et al. Among authors: gerolymatou n. Ann Rheum Dis. 2022 Jul;81(7):1013-1016. doi: 10.1136/annrheumdis-2021-221539. Epub 2021 Nov 10. Ann Rheum Dis. 2022. PMID: 34758975
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.
Papagoras C, Zioga N, Papadopoulos V, Gerolymatou N, Kalavri E, Bounos C, Simopoulou T, Fragoulis GE, Panopoulos S, Fragiadaki K, Evangelatos G, Bournia VK, Arida A, Karamanakos A, Pappa M, Kravvariti E, Deftereou K, Kougkas N, Zampeli E, Kataxaki E, Melissaropoulos K, Barouta G, Panagiotopoulos A, Koutsianas C, Liossis SN, Georgiou P, Dimitroulas T, Tektonidou MG, Bogdanos DP, Elezoglou A, Voulgari PV, Sfikakis PP, Vassilopoulos D. Papagoras C, et al. Among authors: gerolymatou n. Clin Rheumatol. 2023 Dec;42(12):3375-3385. doi: 10.1007/s10067-023-06769-4. Epub 2023 Sep 21. Clin Rheumatol. 2023. PMID: 37731083 Free PMC article.